HIV Coinfection
  • Featured content
    Watch Mark S. Sulkowski, MD; Ira M. Jacobson, MD; and Nancy Reau, MD, FAASLD, AGAF, discuss evolving clinical data on the management of HCV infection in harder-to-treat patient populations, including patients with compensated or decompensated cirrhosis, renal impairment, genotype 3 HCV infection, and HIV coinfection.
  • Featured content
    In this downloadable slideset, Jordan J. Feld, MD, MPH; Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD; and Stefan Zeuzem, MD, review key studies on currently approved HCV therapies presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.
    Date Posted: 5/11/2015
  • Featured content
    In this expert analysis, Jordan J. Feld, MD, MPH; Paul Y. Kwo, MD; and Stefan Zeuzem, MD, discuss the most clinically relevant data on the management of hepatitis C infection in patients with advanced liver disease, cirrhosis, liver transplantation, and HIV coinfection, as well as new advances in the treatment of hepatitis D infection.
  • With a new generation of all-oral HCV therapies entering clinical practice, keeping alert to potential interactions with antiretrovirals and other common medications is part and parcel of managing patients with HIV/HCV coinfection
    Date Posted: 12/29/2014
  • Featured content
    There is great interest in offering coinfected patients the same opportunity for cure as monoinfected patients. The AASLD/IDSA guidance has developed recommendations aimed at maximizing cure in different populations of coinfected individuals.
    Date Posted: 10/9/2014
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 86 Shown
10 of 86 Shown
Show 10 More
Loading...